Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

Metastases, Neoplasm Clinical Trial

Official title:

Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02265549
• Other study ID #: Radiomics SRT 09-2014
• Status: Completed
• Phase: N/A
• First received: October 1, 2014
• Last updated: January 25, 2018
• Start date: May 2014
• Est. completion date: September 4, 2014

Study information

• Verified date: January 2018
• Source: Maastricht Radiation Oncology
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.

Description:

Sensitivity is low for prediction of long term survival of currently available prognostic scores for brain metastases. First the current clinical models will be optimized with a new prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. These tumor characteristics may reflect tumor biology and outcome. Therefore it is investigated if radiomics improves prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics for local failure is investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 155
• Est. completion date: September 4, 2014
• Est. primary completion date: September 4, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cerebral metastasized patients

Exclusion Criteria:

Related Conditions & MeSH terms

• Metastases, Neoplasm
• Neoplasm Metastasis
• Neoplasms, Second Primary

Locations

Country	Name	City	State
Netherlands	Maastro Clinic	Maastricht

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht Radiation Oncology

Country where clinical trial is conducted

Netherlands, 

References & Publications (3)

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. Decoding tumour phenotype by noninvasive imag — View Citation

Rodrigues G, Zindler J, Warner A, Lagerwaard F. Recursive partitioning analysis for the prediction of stereotactic radiosurgery brain metastases lesion control. Oncologist. 2013;18(3):330-5. doi: 10.1634/theoncologist.2012-0316. Epub 2013 Feb 19. — View Citation

Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013 Mar;106(3):370-4. doi: 10.1016/j. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Area under the curve of published prognostic scores	Area under the curve published prognostic scores	1 year
Other	Mismatch rate of published prognostic scores	Mismatch rate of published prognostic scores	1 year
Primary	Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics	Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.	1 year
Primary	Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics	Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.	1 year
Secondary	Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	1 year
Secondary	Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	1 year
Secondary	Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	1 year